

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Boceprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	23686-00026	Date of first issue: 21.10.2014

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Boceprevir Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-
stance/Mixture : Pharmaceutical

Recommended restrictions
on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
Kilsheelan
Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person
responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 2 H361f: Suspected of damaging fertility.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Warning

Hazard statements : H361f Suspected of damaging fertility.

Precautionary statements : **Prevention:**

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Boceprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	23686-00026	Date of first issue: 21.10.2014

P201 Obtain special instructions before use.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Hazardous components which must be listed on the label:

Boceprevir

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Boceprevir	394730-60-0	Repr. 2; H361f	>= 50 - < 70
Sodium dodecyl sulphate	151-21-3 205-788-1	Acute Tox. 4; H302 Skin Irrit. 2; H315 Eye Dam. 1; H318 Aquatic Chronic 3; H412 specific concentration limit Eye Irrit. 2; H319	>= 3 - < 10

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Boceprevir Formulation

Version 4.4	Revision Date: 14.04.2025	SDS Number: 23686-00026	Date of last issue: 28.09.2024 Date of first issue: 21.10.2014
----------------	------------------------------	----------------------------	---

		10 - < 20 % Eye Dam. 1; H318 ≥ 20 % Acute toxicity estimate Acute oral toxicity: 1.200 mg/kg	
--	--	---	--

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

- | | |
|----------------------------|---|
| General advice | : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice. |
| Protection of first-aiders | : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8). |
| If inhaled | : If inhaled, remove to fresh air.
Get medical attention. |
| In case of skin contact | : In case of contact, immediately flush skin with plenty of water. Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse. |
| In case of eye contact | : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists. |
| If swallowed | : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water. |

4.2 Most important symptoms and effects, both acute and delayed

- | | |
|-------|---|
| Risks | : Dust contact with the eyes can lead to mechanical irritation.

Suspected of damaging fertility. |
|-------|---|

4.3 Indication of any immediate medical attention and special treatment needed

- | | |
|-----------|---|
| Treatment | : Treat symptomatically and supportively. |
|-----------|---|

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Boceprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	23686-00026	Date of first issue: 21.10.2014

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Metal oxides
Sulphur oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Boceprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	23686-00026	Date of first issue: 21.10.2014

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures	: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	: Use only with adequate ventilation.
Advice on safe handling	: Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers	: Keep in properly labelled containers. Store locked up. Store in accordance with the particular national regulations.
Advice on common storage	: Do not store with the following product types: Strong oxidizing agents

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Boceprevir Formulation

Version 4.4 Revision Date: 14.04.2025 SDS Number: 23686-00026 Date of last issue: 28.09.2024
Date of first issue: 21.10.2014

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Dust 5 mg/m³
Value type (Form of exposure): TWA (respirable dust)
Basis: FOR-2011-12-06-1358

10 mg/m³
Value type (Form of exposure): TWA (total dust)
Basis: FOR-2011-12-06-1358

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Boceprevir	394730-60-0	TWA	2 mg/m ³ (OEB 1)	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health effects	Value
Sodium dodecyl sulphate	Workers	Inhalation	Long-term systemic effects	285 mg/m ³
	Workers	Skin contact	Long-term systemic effects	4060 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	85 mg/m ³
	Consumers	Skin contact	Long-term systemic effects	2440 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	24 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Sodium dodecyl sulphate	Fresh water	0,176 mg/l
	Freshwater - intermittent	0,055 mg/l
	Marine water	0,018 mg/l
	Sewage treatment plant	1,35 mg/l
	Fresh water sediment	6,97 mg/kg dry weight (d.w.)
	Marine sediment	0,697 mg/kg dry weight (d.w.)
	Soil	1,29 mg/kg dry weight (d.w.)

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Boceprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	23686-00026	Date of first issue: 21.10.2014

8.2 Exposure controls

Engineering measures

Ensure adequate ventilation, especially in confined areas.
Minimize workplace exposure concentrations.
Apply measures to prevent dust explosions.
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

Personal protective equipment

Eye/face protection	:	Wear the following personal protective equipment: Safety goggles Equipment should conform to NS EN 166
Hand protection	:	
Material	:	Chemical-resistant gloves
Remarks	:	Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.
Skin and body protection	:	Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).
Respiratory protection	:	If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to NS EN 143
Filter type	:	Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	powder
Colour	:	white
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Boceprevir Formulation

Version 4.4	Revision Date: 14.04.2025	SDS Number: 23686-00026	Date of last issue: 28.09.2024 Date of first issue: 21.10.2014
----------------	------------------------------	----------------------------	---

Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	Not applicable
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	No data available
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
pH	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Solubility(ies)	:	
Water solubility	:	No data available
Solubility in other solvents	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Vapour pressure	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Relative vapour density	:	Not applicable
Particle characteristics	:	
Particle size	:	No data available

9.2 Other information

Explosives	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Evaporation rate	:	No data available
Molecular weight	:	No data available

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Boceprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	23686-00026	Date of first issue: 21.10.2014

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg
Method: Calculation method

Components:

Boceprevir:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg
LD50 (Monkey): > 1.000 mg/kg

Sodium dodecyl sulphate:

Acute oral toxicity : LD50 (Rat): 1.200 mg/kg
Method: OECD Test Guideline 401

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Boceprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	23686-00026	Date of first issue: 21.10.2014

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg
Method: OECD Test Guideline 402
Remarks: Based on data from similar materials

Skin corrosion/irritation

Not classified based on available information.

Components:

Boceprevir:

Species : Rabbit
Result : No skin irritation

Sodium dodecyl sulphate:

Species : Rabbit
Result : Skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Boceprevir:

Species : Rabbit
Result : Mild eye irritation

Sodium dodecyl sulphate:

Species : Rabbit
Method : OECD Test Guideline 405
Result : Irreversible effects on the eye

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Boceprevir:

Test Type : Maximisation Test
Species : Guinea pig
Result : negative

Sodium dodecyl sulphate:

Test Type : Maximisation Test
Exposure routes : Skin contact

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Boceprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	23686-00026	Date of first issue: 21.10.2014

Species	:	Guinea pig
Result	:	negative
Remarks	:	Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:

Boceprevir:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	---	--

	:	Test Type: Chromosomal aberration Result: negative
--	---	---

Genotoxicity in vivo	:	Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative
----------------------	---	---

Sodium dodecyl sulphate:

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Method: OECD Test Guideline 471 Result: negative
-----------------------	---	---

	:	Test Type: In vitro mammalian cell gene mutation test Result: negative
--	---	---

Genotoxicity in vivo	:	Test Type: Rodent dominant lethal test (germ cell) (in vivo) Species: Mouse Application Route: Ingestion Result: negative
----------------------	---	--

Carcinogenicity

Not classified based on available information.

Components:

Boceprevir:

Species	:	Mouse
Application Route	:	Oral
Exposure time	:	72 Weeks
Dose	:	650 mg/kg body weight
Result	:	negative

Species	:	Rat
Application Route	:	Oral
Exposure time	:	104 Weeks
Dose	:	125 mg/kg body weight
Result	:	negative

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Boceprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	23686-00026	Date of first issue: 21.10.2014

Sodium dodecyl sulphate:

Species	:	Rat
Application Route	:	Ingestion
Exposure time	:	2 Years
Method	:	OECD Test Guideline 453
Result	:	negative
Remarks	:	Based on data from similar materials

Reproductive toxicity

Suspected of damaging fertility.

Components:

Boceprevir:

Effects on fertility	:	Test Type: Fertility/early embryonic development Species: Rat, male Fertility: LOAEL: 75 mg/kg body weight Symptoms: Effects on fertility Result: positive
		Test Type: Fertility/early embryonic development Species: Rat, female Fertility: LOAEL: 150 mg/kg body weight Symptoms: Effects on fertility Result: positive
Effects on foetal development	:	Test Type: Development Species: Rabbit, male and female Application Route: Oral Developmental Toxicity: NOAEL: 300 mg/kg body weight Result: negative
Reproductive toxicity - Assessment	:	Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

Sodium dodecyl sulphate:

Effects on fertility	:	Test Type: Two-generation reproduction toxicity study Species: Rat Application Route: Ingestion Method: OECD Test Guideline 416 Result: negative Remarks: Based on data from similar materials
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Result: negative Remarks: Based on data from similar materials

STOT - single exposure

Not classified based on available information.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Boceprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	23686-00026	Date of first issue: 21.10.2014

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Boceprevir:

Species	: Monkey
NOAEL	: > 200 mg/kg
Application Route	: Oral
Exposure time	: 365 d
Remarks	: No significant adverse effects were reported

Species	: Rat
NOAEL	: 75 mg/kg
LOAEL	: 100 mg/kg
Application Route	: Oral
Exposure time	: 90 d
Target Organs	: Testis, Prostate

Species	: Rat
NOAEL	: 15 mg/kg
LOAEL	: 75 mg/kg
Application Route	: Oral
Exposure time	: 180 d
Target Organs	: Testis

Species	: Mouse
NOAEL	: 250 mg/kg
LOAEL	: 500 mg/kg
Application Route	: Oral
Exposure time	: 90 d
Target Organs	: Kidney

Sodium dodecyl sulphate:

Species	: Rat
NOAEL	: 488 mg/kg
Application Route	: Ingestion
Exposure time	: 90 Days
Remarks	: Based on data from similar materials

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Not classified based on available information.

Product:

Assessment : The substance/mixture does not contain components consid-

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Boceprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	23686-00026	Date of first issue: 21.10.2014

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Boceprevir:

Ingestion : Symptoms: Headache, Gastrointestinal disturbance, bitter taste

SECTION 12: Ecological information

12.1 Toxicity

Components:

Boceprevir:

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 9,5 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 9,5 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50 : > 959 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

NOEC : 959 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity) : NOEC: > 9 mg/l
Exposure time: 28 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 7,2 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

Sodium dodecyl sulphate:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 29 mg/l

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Boceprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	23686-00026	Date of first issue: 21.10.2014

Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Ceriodaphnia dubia (water flea)): 5,55 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : ErC50 (Desmodesmus subspicatus (green algae)): > 120 mg/l
Exposure time: 72 h

NOEC (Desmodesmus subspicatus (green algae)): 30 mg/l
Exposure time: 72 h

Toxicity to microorganisms : EC50 : 135 mg/l
Exposure time: 3 h

Toxicity to fish (Chronic toxicity) : NOEC: $\geq 1,357$ mg/l
Exposure time: 42 d
Species: Pimephales promelas (fathead minnow)

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0,88 mg/l
Exposure time: 7 d
Species: Ceriodaphnia dubia (water flea)

12.2 Persistence and degradability

Components:

Boceprevir:

Biodegradability : Result: Not readily biodegradable.
Biodegradation: 0,6 %
Exposure time: 28 d

Sodium dodecyl sulphate:

Biodegradability : Result: Readily biodegradable.
Biodegradation: 95 %
Exposure time: 28 d
Method: OECD Test Guideline 301B

12.3 Bioaccumulative potential

Components:

Boceprevir:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 2,6
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 3,18

Sodium dodecyl sulphate:

Partition coefficient: n-octanol/water : log Pow: 0,83

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Boceprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	23686-00026	Date of first issue: 21.10.2014

12.4 Mobility in soil

Components:

Boceprevir:

Distribution among environmental compartments : log K_{oc}: 1,9
Method: OECD Test Guideline 106

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product	: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Boceprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	23686-00026	Date of first issue: 21.10.2014

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

14.2 UN proper shipping name

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

14.4 Packing group

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA (Cargo) : Not regulated as a dangerous good

IATA (Passenger) : Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Not applicable

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). : Not applicable

REACH - List of substances subject to authorisation : Not applicable

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Boceprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	23686-00026	Date of first issue: 21.10.2014

(Annex XIV)

Regulation (EU) No 2024/590 on substances that deplete the ozone layer : Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals : Not applicable

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.
Not applicable

Other regulations:

Note the Working Environment Act § 4-1 and § 4-2 on requirements for the employer to protect pregnant employees against discomfort and injury as a result of the work situation and the working environment.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

H302 : Harmful if swallowed.
H315 : Causes skin irritation.
H318 : Causes serious eye damage.
H361f : Suspected of damaging fertility.
H412 : Harmful to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity
Aquatic Chronic : Long-term (chronic) aquatic hazard
Eye Dam. : Serious eye damage
Repr. : Reproductive toxicity
Skin Irrit. : Skin irritation
FOR-2011-12-06-1358 : Norway. Occupational Exposure limits
FOR-2011-12-06-1358 / TWA : Long term exposure limit

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Boceprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	23686-00026	Date of first issue: 21.10.2014

Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Repr. 2

H361f

Classification procedure:

Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Boceprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
4.4	14.04.2025	23686-00026	Date of first issue: 21.10.2014
